XOMA Corp (XOMA) Receives Consensus Rating of “Hold” from Analysts

XOMA Corp (NASDAQ:XOMA) has earned an average rating of “Hold” from the seven research firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $26.13.

Several research firms have commented on XOMA. HC Wainwright set a $36.00 price objective on XOMA and gave the stock a “buy” rating in a research report on Friday, October 19th. Wedbush restated an “outperform” rating on shares of XOMA in a research report on Monday, September 17th. ValuEngine lowered XOMA from a “hold” rating to a “sell” rating in a research report on Friday, September 7th. S&P Equity Research decreased their target price on XOMA from $18.74 to $16.26 in a research report on Tuesday, August 14th. Finally, Zacks Investment Research lowered XOMA from a “hold” rating to a “sell” rating in a research report on Saturday, August 11th.

Large investors have recently made changes to their positions in the company. Allianz Asset Management GmbH lifted its position in shares of XOMA by 32.7% during the 1st quarter. Allianz Asset Management GmbH now owns 12,245 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 3,020 shares in the last quarter. Alps Advisors Inc. lifted its position in shares of XOMA by 82.6% during the 2nd quarter. Alps Advisors Inc. now owns 19,946 shares of the biotechnology company’s stock valued at $542,000 after buying an additional 9,024 shares in the last quarter. Dynamic Technology Lab Private Ltd lifted its position in shares of XOMA by 57.6% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,112 shares of the biotechnology company’s stock valued at $420,000 after buying an additional 7,349 shares in the last quarter. ClariVest Asset Management LLC lifted its position in shares of XOMA by 25.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 23,500 shares of the biotechnology company’s stock valued at $490,000 after buying an additional 4,700 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of XOMA during the 2nd quarter valued at approximately $568,000. Hedge funds and other institutional investors own 43.49% of the company’s stock.

XOMA stock opened at $12.67 on Thursday. The company has a debt-to-equity ratio of 3.06, a quick ratio of 12.46 and a current ratio of 12.46. XOMA has a 12 month low of $11.88 and a 12 month high of $37.25. The company has a market capitalization of $107.27 million, a price-to-earnings ratio of 12.93 and a beta of 2.75.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.03). XOMA had a return on equity of 379.39% and a net margin of 43.55%. The company had revenue of $2.26 million during the quarter, compared to analysts’ expectations of $4.57 million. Sell-side analysts expect that XOMA will post -1.14 earnings per share for the current year.

XOMA Company Profile

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

Further Reading: Reverse Stock Split

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply